Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05785754 · ClinicalTrials.gov registry record · Phase 1
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
A Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by DynamiCure Biotechnology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT05785754: Recruiting Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by DynamiCure Biotechnology.
NCT05785754 is a Phase 1 study of Advanced or Metastatic Solid Tumors that is actively recruiting participants, run by DynamiCure Biotechnology. The registered enrollment target is 320 participants, above the 220-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05785754, a Phase 1 study of Advanced or Metastatic Solid Tumors, is actively recruiting participants, sponsored by DynamiCure Biotechnology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors. The study consists of an Escalation Phase (Phase 1a) and a Dose Expansion/Optimization Phase (Phase 1b).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Doxorubicin
- DRUG Tebentafusp
- DRUG DCSZ11
Study Locations (20)
Arizona
- Mayo Clinic - Phoenix
- HonorHealth - Scottsdale
Colorado
- University of Colorado - Aurora
- Sarah Cannon Research Institute Denver Healthone - Denver
Florida
- Mayo Clinic - Jacksonville
- University of Miami - Miami
New South Wales
- Scientia Clinical Research - Randwick
- St Vincent's Hospital - Sydney
South Australia
- Southern Oncology Clinical Research Unit (SOCRU) - Bedford Park
- The Queen Elizabeth Hospital (TQEH) - Woodville South
Alabama
- University of Alabama - Birmingham
Connecticut
- Yale Cancer Center - New Haven
Maryland
- John Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2023-06-28 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT05785754 shows while recruiting
NCT05785754 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 220-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05785754 names 20 study sites across 15 states, led by Arizona, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT05785754 about?
NCT05785754 is a clinical study titled "DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors". This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors. The study consists of an Escalation Phase (Phase 1a) and a Dose Expansion/Optimization Phase (Phase 1b).
What is the current status of trial NCT05785754?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 320 participants. The study started on 2023-06-28. Estimated completion is 2026-12.
What conditions does trial NCT05785754 study?
This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumors.
What interventions are being tested in trial NCT05785754?
The interventions under investigation include: Pembrolizumab (DRUG), Doxorubicin (DRUG), Tebentafusp (DRUG), DCSZ11 (DRUG).
Who is sponsoring clinical trial NCT05785754?
This trial is sponsored by DynamiCure Biotechnology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05785754 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05785754's enrollment target sits among peer trials
320 2nd of 19 the highest of 19 other Advanced or Metastatic Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced or Metastatic Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RECRUITING · Phase 1
-
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI